PolarisDMD CLINICAL TRIAL

We are honored and proud to be members of the Duchenne muscular dystrophy (DMD) community – one that is built on strength and determination. We strive to discover, develop and bring to patients therapies that will make a meaningful difference in the lives of those who are affected by this disease.

SIGN UP to receive information about edasalonexent and our clinical trials

DOWNLOAD our latest Catabasis Connection newsletter about edasalonexent

The Phase 3 PolarisDMD trial

The Phase 3 PolarisDMD trial evaluated the safety and efficacy of edasalonexent as a potential novel treatment for Duchenne. The trial enrolled 131 boys ages 4-7 (up to 8th birthday) regardless of mutation who had not been on steroids for at least 6 months. The PolarisDMD trial had clinical trial sites across 8 countries located in the United States, Canada, United Kingdom, Ireland, Sweden, Germany, Israel, and Australia. The trial was randomized, double-blind and placebo-controlled, with 2 boys receiving edasalonexent for each boy who received placebo. The primary endpoint for the trial was change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo, and the trial also included timed function tests of muscle function, as well as additional assessments of growth, cardiac function, bone health, and quality of life. After 12 months on the study, all boys had the option to receive edasalonexent in an open-label extension, GalaxyDMD. Top-line results for the PolarisDMD study were shared in Q4 of 2020, and the results are available here.

Global Phase 3 Clinical Sites

PolarisDMD: Fully Launched!

For additional information, please visit clinicaltrials.gov

Making DMD Community Connections

Jett Foundation will be hosting a virtual, week-long World Duchenne Awareness Day (WDAD) celebration from September 7th through September 11th. For the past 5 years, Jett Foundation has hosted this event in the Boston area, however, due to COVID-19 the event will be entirely virtual, and all are welcome to join! Catabasis will be participating in WDAD events throughout the week and spreading awareness about this year’s theme, Duchenne and the Brain.

Parent Project Muscular Dystrophy is bringing their End Duchenne Tour virtual! In an effort to reach every single family facing a Duchenne diagnosis in the US, PPMD has launched a multi-year campaign called the End Duchenne Tour, which brings updates on research, advocacy, and care to cities across the country and features a roster of experts in the Duchenne space. Catabasis will be presenting virtually on September 12th in Portland, Oregon.

Scroll to Top